Certified by Founder Lodge
Alexandria Real Estate Equities, Inc.
United States - Pasadena, California
INVESTOR
1 Disclosed Funding Rounds $100,000,000
60 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Alexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® urban office real estate investment trust (REIT), pioneered the life science real estate niche and remains the longest-tenured ow
| Company | Date | Round | Raised |
|---|---|---|---|
 Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
 Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
 Leal Therapeutics |
October, 31 ,2024 | Unknown | $45,000,000 |
 Matchpoint Therapeutics |
October, 17 ,2022 | Series A | $100,000,000 |
 Ensoma |
February, 06 ,2023 | Series B | $85,000,000 |
 Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
 TwoStep Therapeutics |
June, 26 ,2024 | Seed | $6,500,000 |
 CrossBridge Bio |
November, 05 ,2024 | Unknown | $10,000,000 |
 Function Oncology |
April, 13 ,2023 | Series A | $28,000,000 |
 Georgiamune Inc. |
August, 10 ,2023 | Series A | $75,000,000 |
 Outpace Bio |
August, 02 ,2024 | Series B | $144,000,000 |
 Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
 Orbital Therapeutics |
April, 27 ,2023 | Unknown | $270,000,000 |
 Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
 Archon Biosciences |
October, 31 ,2024 | Seed | $20,000,000 |
 Remedy Plan Therapeutics |
May, 14 ,2025 | Unknown | $18,000,000 |
| Boundless Bio |
May, 17 ,2023 | Series C | $100,000,000 |
 Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
| Leal Therapeutics |
October, 31 ,2024 | Unknown | $45,000,000 |
 Ability Biologics |
December, 07 ,2023 | Seed | $12,000,000 |
| Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
 Tome Biosciences |
December, 14 ,2023 | Series B | $213,000,000 |
| CrossBridge Bio |
November, 05 ,2024 | Unknown | $10,000,000 |
 Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
| Georgiamune Inc. |
August, 10 ,2023 | Series A | $75,000,000 |
 Tr1X |
January, 19 ,2024 | Series A | $75,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
 Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
| Alto Neuroscience |
November, 22 ,2023 | Series C | $45,000,000 |
 Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| Remedy Plan Therapeutics |
May, 14 ,2025 | Unknown | $18,000,000 |
 Mirador Therapeutics |
March, 26 ,2024 | Unknown | $400,000,000 |
| Odyssey Therapeutics |
December, 06 ,2023 | Series C | $101,000,000 |
 OverT Bio |
May, 07 ,2024 | Seed | $16,000,000 |
| Ability Biologics |
December, 07 ,2023 | Seed | $12,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
| Tome Biosciences |
December, 14 ,2023 | Series B | $213,000,000 |
| TwoStep Therapeutics |
June, 26 ,2024 | Seed | $6,500,000 |
| Remix Therapeutics |
January, 04 ,2024 | Unknown | $60,000,000 |
| Outpace Bio |
August, 02 ,2024 | Series B | $144,000,000 |
| Tr1X |
January, 19 ,2024 | Series A | $75,000,000 |
| Archon Biosciences |
October, 31 ,2024 | Seed | $20,000,000 |
| Elo Life Systems |
January, 25 ,2024 | Series A | $20,500,000 |
| Leal Therapeutics |
October, 31 ,2024 | Unknown | $45,000,000 |
| Capstan Therapeutics |
March, 21 ,2024 | Series B | $175,000,000 |
| CrossBridge Bio |
November, 05 ,2024 | Unknown | $10,000,000 |
| Mirador Therapeutics |
March, 26 ,2024 | Unknown | $400,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| OverT Bio |
May, 07 ,2024 | Seed | $16,000,000 |
| Remedy Plan Therapeutics |
May, 14 ,2025 | Unknown | $18,000,000 |
| Delphia Therapeutics |
May, 07 ,2024 | Series A | $67,000,000 |
 Affinia Therapeutics |
October, 10 ,2025 | Series C | $40,000,000 |
| TwoStep Therapeutics |
June, 26 ,2024 | Seed | $6,500,000 |
| Outpace Bio |
August, 02 ,2024 | Series B | $144,000,000 |
| Archon Biosciences |
October, 31 ,2024 | Seed | $20,000,000 |
| Leal Therapeutics |
October, 31 ,2024 | Unknown | $45,000,000 |
| CrossBridge Bio |
November, 05 ,2024 | Unknown | $10,000,000 |
| Umoja Biopharma |
January, 21 ,2025 | Series C | $100,000,000 |
| Remedy Plan Therapeutics |
May, 14 ,2025 | Unknown | $18,000,000 |
| Affinia Therapeutics |
October, 10 ,2025 | Series C | $40,000,000 |
Properly
Nabr
Mudafy
Latchel
Casavo
Sizable Energy | $8,000,000 | (Oct 24, 2025)
Sumble | $38,500,000 | (Oct 24, 2025)
Syntracts | $5,300,000 | (Oct 24, 2025)
Cybrid | $10,000,000 | (Oct 24, 2025)
Elevara Medicines | $70,000,000 | (Oct 24, 2025)
